Amplia Therapeutics Ltd (PK) (INNMF) Share Price

why no action over here.....................

Renee

Thank you.

I gather somewhere around 41 million shares now.

Echo20

Since Amplia Therapeutics Ltd. is not registered with the SEC you should check with OTC Markets to see what the company discloses for their Authorized and Outstanding Shares.

Amiran

Do post when you know.

Echo20

Renee

Do you have the total share count?

Echo20

Innate Immunotherapeutics Ltd. changed to Amplia Therapeutics Ltd.:

http://otce.finra.org/DLSymbolNameChanges

Hope he goes to jail for years. This is what makes the market a nasty mess and what many other do but do not get caught.

https://www.msn.com/en-us/news/us/new-york-gop-rep-chris-collins-arrested-on-insider-trading-charges/ar-BBLENIL?ocid=spartanntp

15 shares of this traded today?

FIFTEEN ?

Has anyone ever seen such a botch of a post Reverse Stock Split as INNMF ?

ETrade shares on hold - The last couple days all my shares have the #H in front of them, so something is still being worked out by INNMF. I hope to come out of it with a share price that's reflective of the new cap.

all true

My point is that this stock didnt close at a pre split price then gap open to reflect the post reverse split price.

The shares have been trading on a daily basis slowly trending up and they have been trading extremely volatile such as today.

This is not how a reverse stock split works.

I listened to the shareholder conference call. The number of shares went from 225m before the reverse split, which then went to 22.5m + the 18.5m additional shares issues for the Amplia acquisition. So basically it went from 225m to 41m. So it seems like the 10:1 split was really more like 5.5:1. Hopefully the share price will come to reflect that. I know my shares aren't showing on etrade today so I think *something* is going on. It seems like the price should be something around $1.1 when the smoke clears. But I don't know...

This has got to be one of the most God awful, completely mismanaged post reverse split stock I have ever witnessed.

Does this price action have any bearing on reality to you Long's here?

That's kind of what I figured, but then I thought that maybe part of the acquisition of Amplia and that it was essentially funded via the reverse split.

It’ll price equal to the market cap on ASX. I don’t know if INNMF shares have even adjusted yet. Apparently there’s trade set up involving foreign reverse splits though. If anybody caught that

how/when? Do you mean the market will force it to adjust or that there's a mechanism that the company has to re-price it?

It’ll adjust to the correct price.

I got the new shares today and was sorely disappointed. Essentially, the only difference now is that I have 1/10th of the shares I had previously, but the stock is still the same price. So all those gains from last week are now gone :( is this the cost of the acquisition? This sucks.

Yes lol. Have you gotten your new shares yet?

Is this not the most screwed up reverse split you have ever seen?

ASX RELEASE 4 May 2018
Innate Immunotherapeutics completes acquisition of Amplia Therapeutics
and new Board appointments
Innate Immunotherapeutics Limited (ASX Code: IIL) is pleased to announce that it has today
completed the acquisition of privately owned Melbourne-based biopharmaceutical company Amplia
Therapeutics Pty Ltd (Amplia). As a result of the transaction, the Company will accelerate the
development of Amplia's Focal Adhesion Kinase (FAK) inhibiting drug candidates for application in
immuno-oncology and other indications.
The FAKi candidates AMP886 and AMP945 represent highly attractive compounds for clinical
development possessing excellent potency and drug-like properties, biological selectivity,
bioavailability and manufacturing scale-up potential. Innate has acquired all the shares of Amplia in
exchange for 18,460,308 new ordinary shares issued today by Innate. Following this weeks 10 for 1
share consolidation and the issue of new shares to the Amplia shareholders, Innate now has
41,023,303 shares on issue.
The completion of the Amplia transaction has also occasioned a change in the composition of the
Innate Board. Chris Collins, the Company's previous largest shareholder and director since early
2006, has today retired as a director. "Chris has been a stalwart supporter of Innate for over ten
years and the Company would never have been able to progress the clinical development of our
previous drug candidates without his encouragement and backing. We owe him a very big vote of
thanks." said CEO Simon Wilkinson.
The Company also records its sincere thanks to Elizabeth Hopkins, Andrew Sneddon, and Chairman
Michael Quinn, all of whom are today stepping down from the Board. "Innate's shareholders and our
many other stakeholders have been very well served by this group of committed and very
professional independent directors" said Mr Wilkinson.
Joining the Board’s remaining members Robert Peach and Simon Wilkinson from today are Andrew
Cooke, Chris Behrenbruch, Chris Burns, and Warwick Tong. Mr Cooke, the Company's Secretary since
late 2013, has extensive experience in law, corporate finance, governance and compliance. Mr
Cooke will chair the Company's Audit Committee. Messrs Behrenbruch, Burns, and Tong were
formally directors of Amplia and have a deep knowledge of the FAK assets now owned by Innate.
Each also has over 20 years hands-on experience in the pharmaceutical and biotechnology industry.

$INNMF: OS now 22Million






$INNMF

Thanks!

INNMF on daily list today 1:10 RS

yup, but nothing from FINRA only the DTC

1 for 10 R/S

INNMF looking strong this morning!

ELEASE 26 April 2018
Results of General Meeting
Innate Immunotherapeutics Limited (ASX Code: IIL) is pleased to confirm that each of the resolutions
considered at its General Meeting held earlier today were passed.
Results of the General Meeting are summarised as follows:
# RESOLUTION PASSED/
FAILED
VOTE
SoH*/
POLL
PROXIES
FOR
PROXIES
AGAINST
PROXIES
DISCRETION
PROXIES
ABSTAIN
1 Consolidation of Capital Passed SoH 57,087,386 1,048,247 1,344,637 1,210,868
2 Acquisition of Amplia Passed SoH 59,178,282 25,512 1,344,637 142,707
3 Issue of Consideration
Shares to Amplia Passed SoH 59,112,491 60,892 1,344,637 173,118
4 Appointment of Andrew
Cooke as a Director Passed SoH 58,858,276 61,431 1,398,504 372,927
5 Appointment of Christian
Behrenbruch as a Director Passed SoH 58,376,787 675,512 1,398,504 240,335
6 Appointment of Warwick
Tong as a Director Passed SoH 58,432,754 691,929 1,342,537 223,918
7 Appointment of Christopher
Burns as a Director Passed SoH 58,367,754 675,512 1,407,537 240,335
*Show of Hands
For Further Information:
Mr Simon Wilkinson, CEO
+64 21 661 850
or visit the Innate Immunotherapeutics website at www.innateimmuno.com

Double from here .. building flag

Did I read this correctly that they are asking for a 10:1 split at the Shareholders meeting next month?

$INNMF: Actually Australias Shares were up by 355% at one point

Thanks for the clarification.

We still have another double that can be achieved from here :)

http://www.proactiveinvestors.com.au/companies/news/193673/innate-immunotherapeutics-shares-surge-250-on-cancer-therapy-acquisition-193673.html


FAK is a growing area of focus in Cancer Therapy.
The only other FAK small cap that I'm aware of is $VSTM.
Their market-cap is at $150Million.

$INNMF market cap is only $5Million.
Much more upside can be achieved here with the addition of this new business.

$INNMF

$INNMF are you watching L2? ;)

$INNMF: Price in Australia closed over 150% overnight

This could easily go over $0.10/sh today here on OTC

Got in @.04
Thanks

$INNMF: Not gonna dip now.... was $0.45 last June

Its wound up and the Shorts don't have much to go with now.

Its going over $0.25/sh in due time.


Sat at $0.015 to $0.02 forever.... that was the time.

Cash on hand was enough to warrant it a higher share price.

$INNMF

$INNMF: Price in Australia closed over 150% overnight

This could easily go over $0.10/sh today here on OTC


$INNMF

Thank you buddy

First big dip. Probably will be above yesterday’s close but this trades so light it’ll be hard to see. Just stick a low bid in there if you want some

?? I’m newbie ??
Ok thanks

$INNMF: Read my post from March 12, 2018

That is the only way I know how to answer your question.

Good traders are PROACTIVE..... not REACTIVE.

You will be on a chase today.


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=139222292



$INNMF

$INNMF: Bid-Ask popping 2-3x now


GREAT DAY AHEAD... hope you all bought in the $0.02 levels like me.


https://www.dropbox.com/s/ssfnh3kpuoosrpb/L2-INNMF-1.JPG?dl=0

$INNMF

Hi
How are you?
What will be a good entry price please?

Today will be interesting. This has been sitting in dormant for so long. I hope they don’t screw us on our shares?

I think it is, this is pretty huge. It’s basically a new company now

Excellent...hopefully it’s good enough to start moving this up? It’s been way to long.

Thanks. Phone wasn’t letting me copy

$INNMF: NEWS... Acquisition of 100% of AMPLIA-therapeutics


http://www.innateimmuno.com/irm/PDF/1462_0/FocusonImmunoOncologyampAcquisitionof2DrugCandidates




ASX RELEASE 23 March 2018

Innate Immunotherapeutics refocuses on immuno-oncology and announces
acquisition of two novel cancer drug candidates

https://stockhead.com.au/health/innate-switches-cancer-failed-ms-bid-shares-rocket-148pc/


Innate Immunotherapeutics Limited (ASX Code: IIL) is pleased to announce that it has entered into a
conditional agreement with the shareholders of Amplia Therapeutics Pty Ltd (Amplia) to acquire all
of the shares of Amplia in consideration for the issue of Innate ordinary shares. In acquiring Amplia,
Innate will acquire that company's Focal Adhesion Kinase (FAK) cancer programme. FAK is emerging
as a promising target in cancer therapy.
"Prior to the Company's recently terminated clinical development of MIS416 for multiple sclerosis,
we were also positioning our immune modulating drug as a potential anti-cancer co-therapy" said
Innate's CEO Simon Wilkinson. "In parallel with our MS programme, we monitored the rapid
developments in the immuno-oncology field and continued to support various long running
collaborations in the cancer co-therapy space." "Refocusing on this existing area of our business is a
logical move for the Company and we are particularly excited to be pursuing certain cancers where
the immune system could play an important role in successful treatment strategies" said Mr
Wilkinson.
Amplia has in-licensed two FAK targeting drug candidates (currently referred to as AMP886 and
AMP945) from Cancer Research Technology Limited, a wholly owned subsidiary of Cancer Research
UK. The drug candidates were originally developed by the Melbourne based Cancer Therapeutics
Cooperative Research Centre (CTx). The CRC Program, is an Australian Government initiative
supporting end-user driven research collaborations to address the major challenges facing Australia.
"There have been multiple independent high-quality publications suggesting that the successful
targeting of FAK could increase the efficacy of other immuno-oncology therapies in tumours where
to date they have limited anti-tumour effects as single agents" said Innate director Dr Robert Peach
who led the Company's technical review of the drug candidates. "CTx have done an excellent job
selecting and characterizing AMP886 and AMP945 before licensing them to Cancer Research
Technology Limited. I was impressed at the thoroughness of their work".
Amplia is a privately owned Melbourne-based biopharmaceutical company. Subject to approval by
the shareholders of both Innate and Amplia, Innate will acquire all the shares of Amplia in exchange
for new ordinary shares to be issued by Innate. Following settlement, Amplia shareholders will own
45% of the total issued capital of Innate and Innate expects to have approximately $2 million cash in
hand and no debt. The Board and management of the Company will include representatives from
the current Innate team and the Amplia team.
In the short term and using existing financial resources, the Company will focus on reviewing
opportunities for MIS416 and advancing the preclinical development of at least one of the two
Amplia drug candidates with a view to being 'Phase 1 ready' within approximately 12 months.
Shareholder approval of the proposed transaction will be sought at a General Meeting to be held at
11am on Thursday 26th April at Level 17, 383 Kent St, Sydney. Shareholder approval will also be
sought for a ten into one consolidation of the issued capital of the Company. The Notice of Meeting
for this General Meeting is expected to be despatched on Wednesday 28th March.
Attached to this announcement are further details concerning the proposed transaction, as required
by ASX Listing Rule 11.1.
- End
For Further Information:
Mr Simon Wilkinson
Managing Director and CEO
Email: simon@innateimmuno.com

News out Innate Immunotherapeutics refocuses on immuno-oncology and announces acquisition of two novel cancer drug candidates

News

March-23 Innate Immunotherapeutics refocuses on immuno-oncology and announces acquisition of two novel cancer drug candidates